PRFX vs. HOOK, AEON, SNPX, IMCC, PHXM, BFRI, VYNE, ADXN, ERNA, and RNAZ
Should you be buying PainReform stock or one of its competitors? The main competitors of PainReform include HOOKIPA Pharma (HOOK), AEON Biopharma (AEON), Synaptogenix (SNPX), IM Cannabis (IMCC), PHAXIAM Therapeutics (PHXM), Biofrontera (BFRI), VYNE Therapeutics (VYNE), Addex Therapeutics (ADXN), Ernexa Therapeutics (ERNA), and TransCode Therapeutics (RNAZ). These companies are all part of the "pharmaceutical products" industry.
PainReform vs. Its Competitors
HOOKIPA Pharma (NASDAQ:HOOK) and PainReform (NASDAQ:PRFX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends and profitability.
In the previous week, PainReform had 2 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 2 mentions for PainReform and 0 mentions for HOOKIPA Pharma. PainReform's average media sentiment score of 0.95 beat HOOKIPA Pharma's score of 0.00 indicating that PainReform is being referred to more favorably in the news media.
63.9% of HOOKIPA Pharma shares are held by institutional investors. Comparatively, 37.3% of PainReform shares are held by institutional investors. 3.3% of HOOKIPA Pharma shares are held by insiders. Comparatively, 34.4% of PainReform shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
PainReform has lower revenue, but higher earnings than HOOKIPA Pharma. HOOKIPA Pharma is trading at a lower price-to-earnings ratio than PainReform, indicating that it is currently the more affordable of the two stocks.
HOOKIPA Pharma has a beta of 1.04, meaning that its stock price is 4% more volatile than the S&P 500. Comparatively, PainReform has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
HOOKIPA Pharma presently has a consensus price target of $4.50, suggesting a potential upside of 405.62%. Given HOOKIPA Pharma's stronger consensus rating and higher possible upside, equities analysts clearly believe HOOKIPA Pharma is more favorable than PainReform.
PainReform has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. PainReform's return on equity of 0.00% beat HOOKIPA Pharma's return on equity.
Summary
PainReform beats HOOKIPA Pharma on 8 of the 15 factors compared between the two stocks.
Get PainReform News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRFX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PRFX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PainReform Competitors List
Related Companies and Tools
This page (NASDAQ:PRFX) was last updated on 10/16/2025 by MarketBeat.com Staff
